Aubagio may cause delays in conversion to clinical definite MS by slowing the loss of cortical grey matter.
Patients experienced reduced disease activity when switched to alemtuzumab.
Data show superiority of OCREVUS compared to Rebif in reducing disability progression independent of relapse activity in people with RMS.
Celgene announced new Phase 3 data evaluating the safety and efficacy of ozanimod vs Avonex for RMS.
There are no FDA-approved MS therapies for the pediatric population.
An emerging line of inquiry suggests a potential association between comorbidities and MS relapses, but studies have been limited.
Patients with multiple sclerosis who experience severe fatigue should be screened for obstructive sleep apnea.
In patients with multiple sclerosis, lesions in the right dorsolateral prefrontal cortex may be associated with hypoalgesia, and lesions in the posterior periventricular area, with hyperalgesia.
Researchers believe that environmental factors may impact disease severity characteristics in genetically susceptible populations.
With its 20-minute application time, the BICAMS is one of the few tools available for small centers with only a few staff members who might not be trained in administering neuropsychological tests.
Viral load of Epstien-Barr virus and human herpesvirus 6 may be higher in patients with MS who also have low vitamin D levels.
Neurology Advisor Articles
- Updated Ischemic Stroke Guidelines: Expert Takeaways
- Alternative Genetic Risk Variant for Alzheimer Disease Identified
- Advance Directives for Dementia: Honoring Patient Wishes When You Don't Know What They Are
- Ethical Considerations in New Coma Research
- Poor Sleep Associated With Worse PTSD, Chronic Pain in Youth
- Comparing Reference Points for Deep Brain Stimulation Location in Parkinson Disease
- FDA Approves Clinical Decision Support Tool for Stroke
- US Will Produce Radioisotope for MRI, FDA Says
- Cognitive Decline in Men Linked to Low Serum Sodium
- Solanezumab Every 4 Weeks Does Not Significantly Affect Cognitive Decline in Alzheimer Disease